🚀 go-pugleaf

> [storytop]
>     ------------------------------------------------------------------------
> 
> 
> RESEARCH/ National Cancer Institute CRADA.
> 
>     ------------------------------------------------------------------------
> 
> 
> Source: Health News Daily
> 
> Health News Daily via NewsPage : National Cancer Institute CRADA:
> NCI's Laboratory of Tumor Immunology and Biology seeking partner for
> Cooperative Research & Development Agreement for a "panel of
> monoclonal antibodies generated against tumor-associated antigens for
> use in the therapy and/or diagnosis of a range of human cancers," NCI
> announces in the April 25 Federal Register. Two major MAb groups are
> the focus: MAbs "directed against the pancarcinoma antigen, TAG-72,"
> which is expressed in colorectal, gastric, pancreatic, ovarian,
> endometrial, breast, non-small cell lung and prostate cancers, to name
> some. CC49 is the prototype Mab for this group, NCI says, and
> humanized and other genetically altered variants already have been
> developed. The second MAb group is "directed against human
> carcinoembryonic antigen, which is expressed in the following
> carcinomas: colorectal, pancreatic, gastric, non-small cell lung and
> breast carcinoma." The prototype, NCI says, is COL-1. NCI believes the
> magnitude of the project may require multiple CRADAs, the terms of
> which are anticipated to be three to five years. Proposals must be
> received by June 5. Contact Michael Christini or Mark Noel at
> 301/496-0477 for further information.
> 
> [04-25-95 at 19:18 EDT, Copyright 1995, F-D-C Reports, Inc.]
> 
>     ------------------------------------------------------------------------
> 
> Feedback |Main |Index |Map |SurfNews |Copyright 1995 |Individual, Inc.
> |